In the first half of 2020, the U.S. FDA approved 24 innovative therapies, 6 have been introduced by Chinese pharmaceutical companies in Greater China development!

, July 01, 2020 /PRNewswire-BIOON/ -- According to the Food and Drug Administration's (FDA) Center for Drug Review and Research (CDER), the FDA approved 24 innovative therapies in the first half of 2020In the first half of 2020, theFDAapproved five biologics, including a food allergy immunotherapy (Sevenforzia), ainfluenza vaccine(Audenz), an ABO/Rh blood card (DG Gel 8 ABO/RhD), a recombinant coagulation factor VIIA (Menifi) vaccine, and a hepatitis 4note, more thanof the 24 innovative therapies have been introduced by Chinese pharmaceutical companies to the Greater China development(see red box), including: (1) Zepzelca, the first new chemical entity for small cell lung cancer (SCLC) in 24 years,Green Leaf Pharmaceuticals;(2) Uplizna, the first B cell consuming agent to treat the visual neurospinal corditis spectrum disorder (NMOSD),Haussen Pharmaceuticals;(3) Qinlock - the first four-line gastrointestinal mesoma (GIST) drug,re-ding pharmaceutical;(4) Ongentys - the OKT inhibitor for Parkinson's patients,Fosun Pharmaceuticals
;(5) Pemazyre - the first bile duct cancer target drug,Cinda Bio
;(6) Aykitva - the first GIST precision therapy,cornerstone pharmaceutical, has submitted an application for listing in Chinaevery once in a while, the bio-valley medicine sector will update the statistical tables, hoping that these innovative therapies can enter the Chinese market as soon as possible, benefiting the vast number of patients in China(BioValleyBioon.com)reference: FDA New Drug Database, Bio Valley.